Japan's AGC launches bid for Italian biotech firm Molmed in $267m deal

Japan's AGC launches bid for Italian biotech firm Molmed in $267m deal

Laboratory equipment. Photo: Pixabay

17 March, 2020

Printed by Unregistered user on Tue, 10 Feb 2026 02:08:49 GMT

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

Subscribe to Newsletter

You may also like

Japan's Astellas Pharma buys US biotech Xyphos for $665m

Venture Capital

Japanese biotech firm EdiGENE raises $14.4m in Series B

Read more from Rest of Asia

Policy & Regulations

Japan says companies can rebuff unsolicited bids amid takeover risk concerns

Macquarie boosts Asia wealth team to bring infra funds to clients